Today, 26 June 2025, an Extraordinary General Meeting was held in ODI Pharma AB (publ), reg. no. 559223-1392. Below is a summary of the decisions that were made. All decisions were made with the required majority. The notice to the general meeting and complete proposals are available on the Company's website, www.odipharma.com.
The Board of Directors' proposals for a resolution on a directed issue of shares (item 7)
The meeting approved of the resolution on a directed issue of shares to increase the company's share capital by SEK 70,769.24 through a new issue of 1,769,231 shares. The issue price is set at SEK 0.65 per share.
| Investor | Number of shares |
| Niclas Kappelin | 923 077 |
| Volker Wiederrich (chairman of the board) | 864 154 |
The right to subscribe for shares is granted to the following investors:
The resolution is subject to Chapter 16 of the Swedish Companies Act and requires the approval of shareholders holding at least 90 percent (nine-tenths) of both the votes cast and the shares represented at the general meeting.
The Board of Directors' proposals for a resolution on a directed issue of shares (item 8)
The meeting approved of the resolution on a directed issue of shares to increase the company's share capital by SEK 25 846,16 through a new issue of 646,154 shares. The issue price is set at SEK 1.30 per share.
| Investor | Number of shares |
| Derek Simmross | 307 692 |
| Jan-Mark Edewaard (CEO and board member) | 338 462 |
The right to subscribe for shares is granted to the following investors:
The resolution is subject to Chapter 16 of the Swedish Companies Act and requires the approval of shareholders holding at least 90 percent (nine-tenths) of both the votes cast and the shares represented at the general meeting.
ODI Pharma AB (publ)
THE BOARD OF DIRECTORS
For more information on ODI Pharma, please contact:
Volker Wiederrich, Chairman, ODI Pharma AB
E-mail: info@odipharma.com
ODI Pharma AB
ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.